Gain Therapeutics inc (GANX) - News Archive

: Gain Therapeutics, Inc. (NASDAQ: GANX) has garnered attention at the AD/PD 2025 conference with its recent oral presentation on the promising preclinical data of GT-02287. The data highlights the disease-modifying pot...

Gain Therapeutics Inc. an innovative biotechnology firm focused on developing therapies for neurodegenerative diseases, has announced the appointment of Gene Mack as its new Chief Executive Officer (CEO) and Director. M...

Gain Therapeutics, a pioneering biotechnology firm focused on advancing treatments for neurodegenerative disorders, recently announced the initiation of a Phase 1b clinical trial for its lead candidate, GT-02287. This a...

Groundbreaking Advances in Neurological Therapies At the forefront of neurological research, Gain Therapeutics has unveiled compelling preclinical data on their novel compound, GT-02287, at the highly regarded Neuroscie...

: Gain Therapeutics is set to host a virtual webinar that will address the critical results from its Phase 1 clinical study of GT-02287, a small molecule therapy designed to target glucocerebrosidase (GCase) activity to...

In an exciting advancement for Parkinson’s disease treatment, Gain Therapeutics, Inc. (Nasdaq: GANX) has announced the presentation of groundbreaking preclinical data for its lead drug candidate, GT-02287. These finding...

In the realm of medicinal science, momentous developments often bring forth hope and anticipation. Such is the case with the recent commendable pronouncement from Gain Therapeutics Inc regarding the promising results de...

Gain Therapeutics Achieves Key Milestones in Phase 1 Study of GT-02287, a Promising Small Molecule Therapy for Parkinson s Disease Bethesda, Md. - Gain Therapeutics, Inc. (Nasdaq: GANX), a clinical-stage biotechnology c...

article:Gain Therapeutics, a leading biotechnology company focusing on developing breakthrough therapeutics for neurological disorders, recently presented their latest data at the Federation of European Neuroscience Soc...

Gain Therapeutics Secures $11 Million in Public Offering Gain Therapeutics, a biotechnology company focused on developing novel therapeutics for rare genetic diseases, has announced the pricing of a public offering that...

Gain Therapeutics Announces Proposed Public Offering to Drive Growth and Expand OperationsBETHESDA, Md., June 13, 2024 - Gain Therapeutics, Inc. (Nasdaq: GANX), a leading biotechnology company specializing in the develo...

In recent years, the development of novel therapeutic strategies for Parkinson s disease (PD) has gained significant attention. One such approach involves targeting the glucocerebrosidase (GCase) enzyme, which plays a c...

In a groundbreaking development, Gain Therapeutics, Inc. (Gain) has announced encouraging outcomes from the single ascending dose (SAD) phase of its Phase 1 clinical trial involving GT-02287. As a novel small molecule t...

Gain Therapeutics Bolsters Management Team with Appointment of Chief Medical Officer, Dr. Jonas HannestadBETHESDA, Md., April 01, 2024 - Gain Therapeutics, Inc. (Nasdaq: GANX), a clinical-stage biotechnology company spe...

Gain Therapeutics Makes Groundbreaking Progress in the Treatment of Parkinson s DiseaseGain Therapeutics, a leading biotechnology company, presented groundbreaking data at the AD/PD 2024 Conference, shedding light on th...

Gain Therapeutics, a clinical-stage biotechnology company, has recently initiated the Multiple Ascending Dose (MAD) part of the Phase 1 clinical trial for GT-02287, their lead drug candidate targeting GBA1 Parkinson s d...

Pharmaceutical innovation has once again shown its potential to redefine medical possibilities. Ground-breaking research from Gain Therapeutics has revealed that their therapeutic agent, GT-02287, has demonstrated the p...

Gain Therapeutics, a renowned biotechnology company pioneering the breakthrough discovery and development of allosteric small molecule therapies, has recently provided an operational update through a letter addressed to...

Advancements in Therapeutic Approach for Parkinson s Disease: The Potential of GT-02287:Parkinson s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the brain, leading to...

Press Release: Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis ModelIn an exciting development, Gain Therapeutics has recentl...